All In MedTech

FDA Clearance Tracker · P130018-S004

ProACT™ Adjustable Continence Therapy for Men

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 3, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 3, 2025

Approved

Time to decision

30 days

Received Sep 3, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P130018-S004
Device name
ProACT™ Adjustable Continence Therapy for Men
Applicant location
Plymouth, MN
Received
Sep 3, 2025
Decided
Oct 3, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P130018

Device type

Device class
Class III
Regulation
21 CFR 876.5280

Every decision under product code EZY

FDA's approval statement

As written in FDA's record.

Approval of the modifications to the study protocol including expansion of the study to 10-14 study sites and modifications to the Informed Consent Form for the post-approval study.

Source documents

Other decisions for Uromedica, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.